论文部分内容阅读
目的分析盐酸氨溴索(沐舒坦)雾化吸入治疗老年慢性支气管炎急性发作的疗效及预后。方法选取2014年6月-2015年6月医院收治的老年慢性支气管炎急性发作患者112例,随机分为常规组与沐舒坦组各56例。常规组予庆大霉素+地塞米松+α糜蛋白酶入0.9%氯化钠溶液雾化吸入;沐舒坦组在常规组基础上加用沐舒坦,对比2组临床疗效及症状缓解时间、住院时间。结果沐舒坦组总有效率为94.64%明显高于常规组的78.57%,差异有统计学意义(P<0.05);咳嗽、咯痰缓解时间、喘息缓解时间及住院时间较常规组相比均明显缩短,差异有统计学意义(P<0.05)。结论于常规治疗基础加用沐舒坦雾化吸入可显著提高临床疗效,并缩短临床症状消失时间,预后效果较好,值得推广与应用。
Objective To analyze the efficacy and prognosis of ambroxol hydrochloride inhalation for the treatment of acute episode of senile chronic bronchitis. Methods One hundred and twelve patients with acute exacerbation of chronic bronchitis admitted from June 2014 to June 2015 in our hospital were randomly divided into 56 cases in each group. The conventional group was given gentamycin + dexamethasone + α-chymotrypsin into 0.9% sodium chloride solution for inhalation. Mucosolvan group was given mucosolvan on the basis of conventional group, and the clinical efficacy and symptom relief time were compared between the two groups. time. Results The total effective rate of mucosolvan group was 94.64%, which was significantly higher than that of the conventional group (78.57%) (P <0.05), and the cough, expectoration relief time, wheezing relief time and hospitalization time were significantly higher than those in the conventional group Shortened, the difference was statistically significant (P <0.05). Conclusion In the conventional treatment plus inhalation of mucosolvan can significantly improve the clinical efficacy and shorten the disappearance of clinical symptoms, the prognosis is good, it is worth promoting and application.